setmelanotide (Imcivree)
Jump to navigation
Jump to search
Indications
- treatment of obesity due to 3 rare genetic conditions:
- pro-opiomelanocortin deficiency (POMC deficiency)
- proprotein subtilisin/kexin type 1 deficiency (PCSK1 deficiency)
- leptin receptor deficiency (LEPR deficiency)
Dosage
- 10 mg/mL injectable solution
Adverse effects
- injection site reactions
- skin hyperpigmentation
- headache
- gastrointestinal effects
- less common:
Mechanism of action
- binds to & activates MC4 receptors in the paraventricular nucleus of the hypothalamus & in the lateral hypothalamic area*
- in addition to reducing appetite, setmelanotide increases resting energy expenditure
- does not increase heart rate or blood pressre ,
* areas involved in regulation of appetite
References
- ↑ RxNorm
- ↑ Wikipedia: Setmelanotide https://en.wikipedia.org/wiki/Setmelanotide
- ↑ Clement K, van den Akker E, Argente J et al Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials Lancet Diabetes Endocrinol. 2020 Dec;8(12):960-970. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33137293 https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30364-8/fulltext